Daxor director awarded 2,500 stock options
Daxor Corp director Joy S. Goudie reported receiving a grant of 2,500 stock options to buy common stock at an exercise price of $10.14 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Daxor Corp director Joy S. Goudie reported receiving a grant of 2,500 stock options to buy common stock at an exercise price of $10.14 per share. The options expire on June 23, 2031 and are scheduled to vest in three annual installments from June 23, 2026 through June 23, 2028. The grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
Insider Trade Summary
Grant/Award: 2,500 shares
Grant/Award
1 txn
Insider
Goudie Joy S.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 2,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (right to buy) — 2,500 options (Direct)
Footnotes (2)
- F1. Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
- F2. The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)
Key Figures
Options granted: 2,500 options
Exercise price: $10.14 per share
Expiration date: June 23, 2031
+4 more
7 metrics
Options granted
2,500 options
Stock options granted to director on June 23, 2026
Exercise price
$10.14 per share
Exercise price for Daxor common stock under the options
Expiration date
June 23, 2031
Option expiration for the 2,500 granted options
Vesting 2026
833 options
First vesting installment on June 23, 2026
Vesting 2027
883 options
Second vesting installment on June 23, 2027
Vesting 2028
834 options
Third vesting installment on June 23, 2028
Post-grant derivative holdings
2,500 options
Total stock options held following this transaction
Key Terms
Stock Options (right to buy), exercise price, expiration date, 2020 Incentive Compensation Plan, +1 more
5 terms
Stock Options (right to buy) financial
"security_title: Stock Options (right to buy)"
exercise price financial
"conversion_or_exercise_price: 10.1400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2031-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
2020 Incentive Compensation Plan financial
"to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan")"
vest financial
"The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DAXOR (DXR) director Joy S. Goudie report?
Joy S. Goudie reported receiving 2,500 stock options as a compensation grant. These options give her the right to buy Daxor common stock at a fixed exercise price and are subject to vesting and plan approval conditions.
What are the key terms of Joy S. Goudie’s DAXOR (DXR) stock options?
The grant covers 2,500 stock options with a $10.14 per share exercise price. The options expire on June 23, 2031 and relate to Daxor’s common stock under the company’s 2020 Incentive Compensation Plan.
How and when do Joy S. Goudie’s DAXOR (DXR) options vest?
The options vest in three tranches: 833 options on June 23, 2026, 883 on June 23, 2027, and 834 on June 23, 2028. Vesting spreads the economic benefit over three years, aligning with longer-term service.
Are Joy S. Goudie’s DAXOR (DXR) option grants subject to any approvals?
Yes. The stock options are contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. This means the grant depends on regulatory clearance of the updated plan terms.
How many DAXOR (DXR) derivative securities does Joy S. Goudie hold after this Form 4?
After this transaction, Goudie holds 2,500 stock options directly according to the filing. This reflects her total reported derivative position related to these options following the grant on June 23, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
